金宇生物技术股份有限公司修订回购注销2023年员工持股计划部分股票数量公告
报告要点
- 公司董事会于2026年4月22日召开会议，审议通过了《关于拟回购注销2023年员工持股计划部分股票及注销回购专用证券账户中部分股票的议案》及相关章程修订。
- 2023年员工持股计划首次授予部分第三个解锁期公司层面业绩考核未达成，导致部分股票需回购注销。
- 原拟回购注销股票数量为906.89万股，修订后为851.84万股；回购价格为6.23元/股。
- 拟同时注销回购专用证券账户中使用期限满三年的回购股份330.16万股。
- 注销后，公司注册资本及股份总数将减少，分别变更为1,099,927,826元和1,099,927,826股（修订后数据）。
- 章程相关条款同步修订，最终股本结构变动以中国证券登记结算公司登记为准。
对股东及股价影响的重要信息
- 股份回购注销：公司将回购注销未解锁员工持股计划股份851.84万股及回购专用账户股份330.16万股，总计注销11,820,000股。这直接减少流通股本，可能对股价产生积极影响。
- 业绩考核未达成影响：首次授予部分第三个解锁期业绩考核未达成，导致相关持股计划未能解锁，表明公司业绩未达标，可能引发市场对公司经营状况的关注。
- 注册资本和总股本减少：注销完成后，公司注册资本和总股本将分别减少至1,099,927,826元和1,099,927,826股，进一步提升每股收益和每股净资产。
- 章程修订：公司章程相关条款同步变更，正式体现公司注册资本和已发行股份数的变化。
- 最终以登记公司数据为准：注销事项尚需股东大会审议，最终以中国证券登记结算公司登记结果为准。
详细内容
金宇生物技术股份有限公司于2026年4月22日召开第十二届董事会第五次会议，审议通过了修订后的股票回购注销议案。由于2023年员工持股计划首次授予部分第三个解锁期业绩考核未达成，11名持有人因个人原因离职，导致相关权益份额无法解锁。原拟回购注销股票数量为906.89万股，现修订为851.84万股，回购价格为6.23元/股。同时，公司拟对回购专用证券账户中期限满三年的回购股份330.16万股予以注销。
本次回购注销总股数为11,820,000股，注销后公司注册资本由1,111,747,826元减少为1,099,927,826元，股份总数由1,111,747,826股减少为1,099,927,826股。本次注销和章程修订事项尚需提交公司股东大会审议，最终以中国证券登记结算公司出具的证券变更登记表为准。
此次公告显示，公司部分业绩目标未达成，影响员工持股计划的解锁和股权激励，可能反映公司阶段性经营压力。同时，股份回购注销有望提升每股收益和每股净资产，对股东利益构成实质影响，具有潜在的股价驱动作用。
免责声明
本文仅为信息披露用途，不构成投资建议。投资者请根据自身情况审慎决策，最终以公司公告及登记公司数据为准。
Jinyu Bio-technology Co., Ltd. Revises Quantity of Shares to Be Repurchased and Cancelled in 2023 Employee Stock Ownership Plan
Key Points
- The Board of Directors held a meeting on April 22, 2026, and approved proposals to repurchase and cancel shares related to the 2023 Employee Stock Ownership Plan (ESOP), as well as amend the Articles of Association.
- The third unlocking period of the first grant under the 2023 ESOP failed to meet company-level performance assessments, resulting in the need to repurchase and cancel certain shares.
- The original proposal was to repurchase and cancel 9.0689 million shares; after revision, the amount is 8.5184 million shares at a repurchase price of RMB 6.23 per share.
- The company also plans to cancel 3.3016 million shares in the special repurchase securities account that have been held for more than three years.
- After the cancellation, the registered capital and total shares of the company will decrease to RMB 1,099,927,826 and 1,099,927,826 shares, respectively (revised data).
- Relevant articles in the Articles of Association will be amended accordingly. The final capital structure will be based on the securities registration confirmation from China Securities Depository and Clearing Corporation.
Important Information for Shareholders and Price Sensitivity
- Share Repurchase and Cancellation: The company will repurchase and cancel 8.5184 million un-unlocked ESOP shares and 3.3016 million repurchase account shares, totaling 11,820,000 shares. This reduces the total shares outstanding and may positively impact share prices.
- Impact of Performance Target Failure: The failure to meet performance targets for the third unlocking period signals operational challenges, which may concern investors about business outlook.
- Decrease in Registered Capital and Share Count: Upon completion, registered capital and total shares will reduce to RMB 1,099,927,826 and 1,099,927,826 shares, potentially enhancing per-share earnings and net asset value.
- Amendment of Articles: The Articles of Association will be updated to reflect changes in registered capital and issued shares.
- Final Confirmation Pending: These amendments require shareholder approval and the final outcome will depend on the confirmation from China Securities Depository and Clearing Corporation.
Detailed Article
Jinyu Bio-technology Co., Ltd. convened its twelfth Board meeting on April 22, 2026, approving revised proposals for share repurchase and cancellation. Due to failure to meet company-level performance targets for the third unlocking period of the first ESOP grant and the departure of 11 participants, the respective share entitlements will not be unlocked. The repurchase quantity was revised from 9.0689 million shares to 8.5184 million shares at RMB 6.23 per share. Additionally, 3.3016 million shares held in the repurchase account for over three years will be cancelled.
In total, 11,820,000 shares will be cancelled, reducing the registered capital and total shares from 1,111,747,826 to 1,099,927,826. The Articles of Association will be amended accordingly, and shareholder approval is required. The final capital structure will be confirmed by the China Securities Depository and Clearing Corporation.
This disclosure signals that certain performance targets were not met, impacting the unlocking and incentives of ESOP participants, which may reflect operational pressures. The share repurchase and cancellation is expected to enhance per-share metrics and shareholder value, potentially affecting share prices.
Disclaimer
This article is for information disclosure purposes only and does not constitute investment advice. Investors should make decisions prudently and refer to official company announcements and registration data for final confirmation.
